Spots Global Cancer Trial Database for Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma

Official Title: Expression of T Immunoregulatory Proteins in ALK+ Anaplastic Large Cell Lymphoma (ALCL)

Study ID: NCT01366170

Conditions

Lymphoma

Interventions

microarray analysis

protein expression analysis

western blotting

flow cytometry

immunohistochemistry staining method

laboratory biomarker analysis

mass spectrometry

Study Description

Brief Summary: RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. it may also help doctors predict how patients will respond to treatment. PURPOSE: This research trial studies biomarker expression in tissue samples from young patients with anaplastic large cell lymphoma.

Detailed Description: OBJECTIVES: * To determine the expression of immunoregulatory proteins including CD4, FOXP3 and CD276 in anaplastic large cell lymphoma (ALCL). * To correlate the expression of these proteins with the levels of anaplastic lymphoma kinase (ALK) autoantibodies in patient of ANHL0131. OUTLINE: Archived tissue microarray samples are analyzed by mass spectrometry and validated by Western blotting, flow cytometry, and IHC.